12 million
cancer patients annually have actionable fusions [1], [2]*.
*Derived from 6.0% of samples druggable fusions detected in a 9,624 sample cohort, extrapolated to 20 million new cancer cases per year globally.
In a study of 1007 plasma samples from over 30 cancer types across the USA and Asia,
ctDNA alone detected only 65% of gene fusions [3].
Tissue biopsy for cancer diagnosis can be hard to access.
1 in 3
NSCLC cases have insufficient tissue yield to perform comprehensive genomic profiling [4].
LiquidHALLMARK is an ultrasensitive blood test designed to detect tumor-derived ctDNA and ctRNA to identify cancer-related mutations and biomarkers with a single blood draw.
LiquidMARK is a focused sub-panel for targeted cancer types. It uses the same test process as LiquidHALLMARK to detect
tumor-derived ctDNA to identify cancer-related mutations and biomarkers with a single blood draw.
LiquidMARK is available internationally outside the USA.
What is ctDNA and ctRNA?
ctDNA is shed by dying cancer cells while ctRNA is actively released by living cancer cells [5]. Combining ctDNA + ctRNA analysis has shown to increase the detection of actionable fusions by 36.7% (11/30) [3].
LIQUIK Prospective Study Demonstrates Utility of Combined ctDNA and ctRNA [6].
Study results showed that
LiquidHALLMARK ctDNA + ctRNA detected 15.6% (52 vs 45) more tissue-confirmed, NCCN guideline-recommended biomarkers* than a FDA-approved ctDNA only test, with 93-100% agreement with tissue NGS.
LiquidHALLMARK ctDNA demonstrated non-inferiority compared to the FDA-approved ctDNA only test, detecting 72.1% (vs 66.1%) of patients with tissue-confirmed NCCN guideline-recommended biomarkers*.
LiquidHALLMARK detected actionable biomarkers in
-
41.9% (13/31) patients with failed tissue biopsy
-
13.0% (6/46) patients deemed tissue NGS negative
Downloads
Specifications
Single Nucleotide Variants (SNVs)
>91%
Sensitivity
>99%
Specificity
0.1% VAF
LOD
Insertions / Deletions (indels)
>90%
Sensitivity
>99%
Specificity
0.1% VAF
LOD
ctDNA fusions
>96%
Sensitivity
>95%
Specificity
0.1% VAF
LOD
ctRNA fusions
>91%
Sensitivity
>99%
Specificity
10 copies
LOD
References:
-
Gao, Q. et al. Cell Reports 2018; 23(1): 227-238.E3.
-
Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263.
-
Chan, D. Paper presented at: ASCO Annual Meeting; June 2, 2025; Chicago, IL.
-
Sehayek et al. IASCLC Liquid Biopsy Oct 2020.
-
Stejskal P, et al. Mol Cancer 2023; 22(15).
-
Samol J, et al. JCO Precis. Oncol. 2025; 9: e2500181.
